690 A First-in-human, Open-Label, Multicenter, Phase 1/2a, Dose-Escalation and Expansion Study of GI-108, a Novel Immunocytokine Combining Anti-Cd73-il2v, in Patients with Metastatic Solid Tumors
Regular and Young Investigator Award Abstracts（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要